
BMS scales back at former Novartis plant, shifting cell therapy vector production to MA
Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS will cease production of viral vectors from its plant in …